Characteristics of patients who did not have GVHD or did not require treatment with steroids
Patient no. . | Age, y + mo . | Sex . | Disease . | Donor (sex) . | Graft source . | Cells/kg, × 108 . | ATG . | Growth factor . | ANC recovery, d . | PLT recovery, d . | Conditioning regimen . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 4 + 5/12 | F | ALL | UD (M) | BM | 4.0 | Y | G-CSF | +15 | +21 | TBI/TT/CY | Dead (relapse) |
| 2 | 8 + 4/12 | M | ALL | UD (F) | BM | 6.3 | Y | G-CSF | +18 | +22 | TBI/TT/CY | Alive |
| 3 | 10 + 5/12 | M | SAA | UD (F) | BM | 6.8 | Y | G-CSF | +17 | +21 | CY/FLU | Alive |
| 4 | 19 | M | Thal | Sibl (M) | BM | 3.0 | N | G-CSF | +18 | +29 | BU/TT/FLU | Alive |
| 5 | 16 | F | SAA | UD (F) | BM | 3.0 | Y | G-CSF | +18 | +22 | CY/FLU | Alive |
| 6 | 5 | M | SAA | Sibl (F) | BM | 6.6 | N | G-CSF | +14 | +19 | CY | Alive |
| 7 | 9 + 3/12 | M | Thal | Sibl (M) | BM | 2.2 | N | G-CSF | +11 | +21 | BU/TT/FLU | Alive |
| 8 | 18 + 7/12 | F | MDS | UD (F) | BM | 2.5 | Y | G-CSF | +18 | +27 | BU/CY/L-PAM | Alive |
| 9 | 9 + 2/12 | F | Thal | Sibl (M) | BM | 4.0 | N | G-CSF | +12 | +16 | BU/TT/FLU | Alive |
| 10 | 7 + 6/12 | M | AML | Sibl (M) | BM | 5.0 | N | G-CSF | +13 | +25 | BU/CY/L-PAM | Alive |
| 11 | 13 + 2/12 | F | ALL | Sibl (M) | BM | 4.8 | N | G-CSF | +9 | +14 | TBI/TT/CY | Alive |
| 12 | 17 + 7/12 | M | ALL | UD (F) | BM | 6.8 | Y | G-CSF | +16 | +34 | TBI/TT/CY | Alive |
| 13 | 1 + 2/12 | F | AML | Sibl (F) | BM | 7.0 | N | Nil | +17 | +22 | BU/CY/L-PAM | Alive |
| 14 | 7 + 6/12 | F | Thal | Sibl (M) | CB | 0.38 | N | Nil | +12 | +17 | BU/TT/FLU | Alive |
| 15 | 7 + 4/12 | M | AML | UD (M) | BM | 2.6 | Y | Nil | +17 | +22 | BU/CY/L-PAM | Alive |
| 16 | 17 + 3/12 | M | ALL | UD (M) | BM | 3.8 | Y | Nil | +17 | +23 | TBI/TT/CY | Dead (relapse) |
| 17 | 14 | M | Thal | Sibl (F) | BM | 4.5 | N | Nil | +16 | +32 | BU/TT/FLU | Alive |
| 18 | 14 + 10/12 | M | SAA | Sibl (M) | BM | 2.2 | N | Nil | +21 | +26 | CY | Alive |
| 19 | 16 + 2/12 | M | AML | Sibl (F) | BM | 2.5 | N | Nil | +17 | +35 | BU/CY/L-PAM | Alive |
| 20 | 17 | F | AML | Sibl (M) | BM | 2.5 | N | Nil | +14 | +27 | BU/CY/L-PAM | Alive |
| 21 | 13 + 3/12 | F | Thal | Sibl (M) | BM | 4.5 | N | Nil | +20 | +20 | BU/TT/FLU | Alive |
| 22 | 3 + 1/12 | M | MDS | UD (F) | BM | 15.0 | Y | Nil | +17 | +22 | BU/CY/L-PAM | Alive |
| 23 | 18 | F | Thal | Sibl (F) | BM | 4.5 | N | Nil | +21 | +33 | BU/TT/FLU | Alive |
| 24 | 13 + 11/12 | F | ALL | UD (M) | BM | 6.0 | Y | Nil | +22 | +22 | TBI/TT/CY | Alive |
| 25 | 8 + 6/12 | F | ALL | UD (M) | BM | 6.3 | Y | Nil | +22 | +29 | TBI/TT/CY | Alive |
| 26 | 11 | M | ALL | Sibl (M) | BM | 9.0 | N | Nil | +13 | +15 | TBI/TT/CY | Alive |
Patient no. . | Age, y + mo . | Sex . | Disease . | Donor (sex) . | Graft source . | Cells/kg, × 108 . | ATG . | Growth factor . | ANC recovery, d . | PLT recovery, d . | Conditioning regimen . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 4 + 5/12 | F | ALL | UD (M) | BM | 4.0 | Y | G-CSF | +15 | +21 | TBI/TT/CY | Dead (relapse) |
| 2 | 8 + 4/12 | M | ALL | UD (F) | BM | 6.3 | Y | G-CSF | +18 | +22 | TBI/TT/CY | Alive |
| 3 | 10 + 5/12 | M | SAA | UD (F) | BM | 6.8 | Y | G-CSF | +17 | +21 | CY/FLU | Alive |
| 4 | 19 | M | Thal | Sibl (M) | BM | 3.0 | N | G-CSF | +18 | +29 | BU/TT/FLU | Alive |
| 5 | 16 | F | SAA | UD (F) | BM | 3.0 | Y | G-CSF | +18 | +22 | CY/FLU | Alive |
| 6 | 5 | M | SAA | Sibl (F) | BM | 6.6 | N | G-CSF | +14 | +19 | CY | Alive |
| 7 | 9 + 3/12 | M | Thal | Sibl (M) | BM | 2.2 | N | G-CSF | +11 | +21 | BU/TT/FLU | Alive |
| 8 | 18 + 7/12 | F | MDS | UD (F) | BM | 2.5 | Y | G-CSF | +18 | +27 | BU/CY/L-PAM | Alive |
| 9 | 9 + 2/12 | F | Thal | Sibl (M) | BM | 4.0 | N | G-CSF | +12 | +16 | BU/TT/FLU | Alive |
| 10 | 7 + 6/12 | M | AML | Sibl (M) | BM | 5.0 | N | G-CSF | +13 | +25 | BU/CY/L-PAM | Alive |
| 11 | 13 + 2/12 | F | ALL | Sibl (M) | BM | 4.8 | N | G-CSF | +9 | +14 | TBI/TT/CY | Alive |
| 12 | 17 + 7/12 | M | ALL | UD (F) | BM | 6.8 | Y | G-CSF | +16 | +34 | TBI/TT/CY | Alive |
| 13 | 1 + 2/12 | F | AML | Sibl (F) | BM | 7.0 | N | Nil | +17 | +22 | BU/CY/L-PAM | Alive |
| 14 | 7 + 6/12 | F | Thal | Sibl (M) | CB | 0.38 | N | Nil | +12 | +17 | BU/TT/FLU | Alive |
| 15 | 7 + 4/12 | M | AML | UD (M) | BM | 2.6 | Y | Nil | +17 | +22 | BU/CY/L-PAM | Alive |
| 16 | 17 + 3/12 | M | ALL | UD (M) | BM | 3.8 | Y | Nil | +17 | +23 | TBI/TT/CY | Dead (relapse) |
| 17 | 14 | M | Thal | Sibl (F) | BM | 4.5 | N | Nil | +16 | +32 | BU/TT/FLU | Alive |
| 18 | 14 + 10/12 | M | SAA | Sibl (M) | BM | 2.2 | N | Nil | +21 | +26 | CY | Alive |
| 19 | 16 + 2/12 | M | AML | Sibl (F) | BM | 2.5 | N | Nil | +17 | +35 | BU/CY/L-PAM | Alive |
| 20 | 17 | F | AML | Sibl (M) | BM | 2.5 | N | Nil | +14 | +27 | BU/CY/L-PAM | Alive |
| 21 | 13 + 3/12 | F | Thal | Sibl (M) | BM | 4.5 | N | Nil | +20 | +20 | BU/TT/FLU | Alive |
| 22 | 3 + 1/12 | M | MDS | UD (F) | BM | 15.0 | Y | Nil | +17 | +22 | BU/CY/L-PAM | Alive |
| 23 | 18 | F | Thal | Sibl (F) | BM | 4.5 | N | Nil | +21 | +33 | BU/TT/FLU | Alive |
| 24 | 13 + 11/12 | F | ALL | UD (M) | BM | 6.0 | Y | Nil | +22 | +22 | TBI/TT/CY | Alive |
| 25 | 8 + 6/12 | F | ALL | UD (M) | BM | 6.3 | Y | Nil | +22 | +29 | TBI/TT/CY | Alive |
| 26 | 11 | M | ALL | Sibl (M) | BM | 9.0 | N | Nil | +13 | +15 | TBI/TT/CY | Alive |
ANC indicates absolute neutrophil count (day of recovery after transplantation); PLT, platelets (day of recovery after transplantation); F, female; ALL, acute lymphoblastic leukemia; UD, unrelated donor; BM, bone marrow; Y, yes; TBI, total body irradiation; TT, thiotepa; CY, cyclophosphamide; M, male; SAA, severe aplastic anemia; FLU, fludarabine; Thal, thalassemia major; Sibl, sibling; N, no; BU, busulfan; MDS, myelodysplastic syndrome; L-PAM, melphalan; AML, acute myelogenous leukemia; and CB, cord blood.